Roche Hldg Ltd Spons (RHHBY) 36.5400 $RHHBY Novartis'

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Roche Hldg Ltd Spons (RHHBY) 36.5400 $RHHBY

Novartis' Heart Failure Drug Entresto Receives FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 08, 11:50AM CDT
Novartis AG (NVS) announced that its heart failure drug Entresto (previously known as LCZ696) has received FDA approval.
ABT: 49.93 (+0.74), JNJ: 99.53 (+1.13), NVS: 103.22 (+3.20)

Premarket Biotech Digest: Arrowhead Initiates Dosing, Vertex Orkambi Approval, Insider Sales
Kanak Kanti De - at Seeking Alpha - Mon Jul 06, 6:28AM CDT

VRTX: 122.95 (+2.06), NVO: 57.68 (+2.91), ISIS: 53.50 (+0.42), ARWR: 6.68 (+0.07), MDCO: 32.73 (-0.24), GILD: 113.74 (+0.38), MRK: 57.95 (+0.57), ABBV: 69.23 (+1.26), GSK: 42.45 (+0.65)

The Weekender
Aviate - at Seeking Alpha - Sun Jul 05, 3:57AM CDT
Greece and Europe It is not over-exaggerating to say that all eyes are on Greece this weekend as the Greek people vote in the referendum. Where it was once seen as the most unlikely of outcomes, there now seems to be a real risk of Grexit,...
GREK: 11.26 (+0.95), TI: 13.19 (+0.48), RYAAY: 73.25 (+1.50), APOL: 14.01 (+0.43), BUD: 126.61 (+6.21), EU: 20.54 (-0.08), VOD: 36.46 (+1.07), PSO: 19.11 (+0.56)

FDA clears upstart Theranos' test system
Seeking Alpha - at Seeking Alpha - Thu Jul 02, 3:07PM CDT

ABT: 49.93 (+0.74), AXDX: 24.91 (+0.13), BIO: 147.97 (+1.27), CBMX: 1.69 (+0.08), CPHD: 58.15 (+0.75), QDEL: 22.74 (+0.40), TRIB: 18.05 (+0.17), QGEN: 25.73 (+1.00), CEMI: 4.97 (+0.08)

Seeking Alpha's Biotech Weekly: Celgene-Juno, Gilead's HIV NDA, Happy 4th!
SA Editor Mike Taylor - Seeking Alpha - Thu Jul 02, 3:00PM CDT
A holiday-shortened week still left biotech investors with plenty to chew over. The start of a decade-long collaboration between Celgene ( CELG ) and Juno Therapeutics ( JUNO ) prompted a new wave of enthusiasm for an already well appreciated CAR-T...
CRMD: 3.78 (+0.16), SGYP: 9.13 (+0.49), MNK: 122.44 (+2.18), BIIB: 388.23 (-11.06), OCAT: 5.22 (+0.14), VRX: 232.32 (+8.93), PRGO: 180.86 (+0.85), VRTX: 122.95 (+2.06), GALT: 2.67 (+0.12), IBB: 372.80 (+6.06), MNKD: 5.38 (+0.25), HNT: 69.12 (+2.32), CELG: 118.84 (+1.97), CNC: 72.91 (+2.06), JNJ: 99.53 (+1.13), MDCO: 32.73 (-0.24), GILD: 113.74 (+0.38), GERN: 4.22 (+0.13), JUNO: 52.05 (+1.72), BXLT: 30.85 (+0.79), EXEL: 3.68 (+0.25), NVS: 103.22 (+3.20)

Exelixis-Roche's Skin Cancer Drug's FDA Review Delayed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 02, 3:00PM CDT
Exelixis Inc.'s (EXEL) announced that the FDA is extending the review period for the new drug application for skin cancer candidate, cobimetinib by three months.
MRK: 57.95 (+0.57), BMY: 69.27 (+1.38), EXEL: 3.68 (+0.25)

Is Avalanche Biotechnologies A Good Buy Now After Phase 2 Results For Its Wet AMD Drug?
Long Term Bio - at Seeking Alpha - Thu Jul 02, 2:33PM CDT

AAVL: 16.25 (+0.62), REGN: 526.01 (+16.98)

Why Exelixis, Inc. Shares Slumped Today
Todd Campbell, The Motley Fool - Motley Fool - Wed Jul 01, 5:21PM CDT
What's Happening: Shares in Exelixis  slumped by 10% earlier today and closed 7% down after the company reported that the FDA is delaying a decision regarding approval of its cobimetinib, a therapy for BRAF V600 mutation-positive advanced...
EXEL: 3.68 (+0.25)

What Is Beyond Vision-Loss Blockbuster For Regeneron?
at Investor's Business Daily - Wed Jul 01, 3:12PM CDT
As people get older, they are more prone to vision loss from age-related macular degeneration. The severe "wet" version of the condition is the leading cause of blindness in the U.S., afflicting millions of people over 55. It's caused by leaky,...
GILD: 113.74 (+0.38), AMGN: 154.10 (+2.79), SNY: 51.49 (+2.71), REGN: 526.01 (+16.98), CELG: 118.84 (+1.97)

Aeterna Zentaris' Endometrial Cancer Study Fully Enrolled - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 01, 1:10PM CDT
Aeterna Zentaris Inc. (AEZS) completed patient enrolment in a phase III ZoptEC study on its oncology candidate zoptarelin doxorubicin.
ABT: 49.93 (+0.74), AEZS: 0.24 (+0.01), AAVL: 16.25 (+0.62)

FDA extends PDUFA date for review of cobimetinib NDA; Exelixis off 8%
Seeking Alpha - at Seeking Alpha - Wed Jul 01, 10:08AM CDT

EXEL: 3.68 (+0.25)

Can Hepatitis B Be A Blockbuster Bug?
at Investor's Business Daily - Wed Jul 01, 7:02AM CDT
The new class of hepatitis C drugs, led by Gilead Sciences (GILD) and AbbVie (ABBV), has turned into one of the biggest success stories in biotech history. Yet hepatitis C is one of only five viruses that cause viral hepatitis. Do any of the others...
INO: 7.46 (+0.19), GBIM: 2.55 (-0.01), ISIS: 53.50 (+0.42), ARWR: 6.68 (+0.07), GILD: 113.74 (+0.38), ASMB: 18.55 (+0.67), TKMR: 11.71 (+0.46), ABBV: 69.23 (+1.26), BMY: 69.27 (+1.38), GSK: 42.45 (+0.65), NVS: 103.22 (+3.20)

Roche's MS drug passes trial
at Investor's Business Daily - Tue Jun 30, 5:54PM CDT
Genentech, the U.S. biotech arm of Swiss pharma giant Roche (RHHBY), said that its drug candidate ocrelizumab had succeeded in cutting the relapse rate for multiple-sclerosis patients in 2 late-stage trials. The goal of the studies was to show...
PFE: 34.36 (+0.50)

The iShares MSCI Switzerland Capped ETF: A Fund Worth Yodeling About
Accendo Markets - at Seeking Alpha - Tue Jun 30, 4:16PM CDT

SWZ: 11.77 (+0.33), CS: 28.75 (+1.00), UBS: 21.86 (+0.67), EWL: 34.00 (+1.10), FSZ: 41.05 (+1.28), ABB: 20.59 (+0.58), SYT: 83.21 (+2.79)

Deforestation Impacting Pharmaceutical Industry
Global Risk Insights - at Seeking Alpha - Tue Jun 30, 3:07PM CDT
Global rainforests hold unknown treasures for fighting and curing multiple diseases. But whilst the complete destruction of the world’s remaining rainforests looms on the horizon, pharmaceutical companies are only slowly beginning to tap this...
AZN: 66.45 (+1.90), PFE: 34.36 (+0.50), MRK: 57.95 (+0.57), XBI: 252.57 (+5.62), IBB: 372.80 (+6.06), GSK: 42.45 (+0.65), BMY: 69.27 (+1.38), SNY: 51.49 (+2.71), NVS: 103.22 (+3.20)

Evotec's Partner Roche Provides Initial Update From Phase IIb Trial in Alzheimer's Disease
GlobeNewswire - Tue Jun 30, 2:27PM CDT
Evotec AG (Frankfurt:EVT) (TecDAX) (ISINE0005664809) was updated today by its partner Roche (SIX:RO) (SIX:ROG) (OTCQX:RHHBY) on the initial results of the Phase IIb trial with Sembragiline (RG1577, EVT302), a MAO-B inhibitor for the treatment of Alzheimer's disease ("AD". In this study, Sembragiline failed to demonstrate benefit on the primary endpoint (Alzheimer's Disease Assessment Scale - Cognitive Behaviour Subscale, ADAS-cog-11) after 52 weeks of treatment. Preliminary safety analyses showed that Sembragiline was well tolerated with no safety signals identified. Roche has initiated a process to evaluate all secondary endpoint read-outs on Sembragiline and to consider all further development options. The multicentre, randomised, double-blind, parallel-group, placebo-controlled Phase IIb study was undertaken to evaluate the efficacy and safety of Sembragiline in patients with moderate severity Alzheimer's disease added on background of AD standard therapy.
EVT: 20.20 (+0.20), ROG: 58.92 (-1.67)

Roche 'High Efficacy' MS Drug Succeeds In Trials
at Investor's Business Daily - Tue Jun 30, 9:42AM CDT
Genentech, the U.S. biotech arm of Swiss pharma giant Roche (RHHBY), announced Tuesday that its drug candidate ocrelizumab had succeeded in cutting the relapse rate for multiple-sclerosis patients in two late-stage trials. The goal of the studies was...
BIIB: 388.23 (-11.06), PFE: 34.36 (+0.50), SNY: 51.49 (+2.71), NVS: 103.22 (+3.20)

Roche's Multiple Sclerosis Studies Meet Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 30, 8:10AM CDT
Roche Holding AG (RHHBY) announced that two phase III studies on multiple sclerosis candidate ocrelizumab met their primary and major secondary endpoints.
ABT: 49.93 (+0.74), PFE: 34.36 (+0.50)

Genentech's ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus interferon beta-1a (Rebif(R)) in Two Phase III Studies in Multiple Sclerosis
Business Wire - Tue Jun 30, 12:00AM CDT
--Genentech will submit data to the U.S. Food and Drug Administration

Roche's Perjeta Recommended for Pre-Surgery Breast Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 29, 3:30PM CDT
Roche's (RHHBY) Perjeta has been recommended by the CHMP as a neoadjuvant treatment of HER2-positive early-stage breast cancer patients.
ABT: 49.93 (+0.74), NVO: 57.68 (+2.91)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

iHeartMedia Faces 65% Drop: Fraud Investigation Launched

Updated Category News Views 40

Trouble Tunes for iHeartMedia Investors Alright folks, here's the skinny on iHeartMedia, Inc. These days, it's like everyone's out for a piece of iHeart, and not in the way you'd wanna see—unless you're SBS Law, those shareholder rights hotshots diving into another pond of legal ripples. Seems a heap of head-scratching's going down on their version of transparency with...

Continue Reading
Disney+ Teams Up with Tiff's: Blue Cookie Debut

Updated Category News Views 52

A Sweet Collaboration on the Horizon If somebody had told me that cookies could conjure up excitement equivalent to a TV show's new season, I'd have laughed. But here we are—Disney+ and Tiff's Treats are cooking up a storm with blue chocolate chip cookies to celebrate 'Percy Jackson and the Olympians' Season 3 premiere. The Cookie That Packs a Punch Forget ordinary...

Continue Reading
Crocs to Present at Key Industry Conferences

Updated Category News Views 48

Crocs Set to Step into the Spotlight Alright, if there's one thing about Crocs, Inc. (NASDAQ: CROX) that never fails to surprise, it's how they constantly keep everyone on their toes. The iconic casual footwear brand with its whimsical, love-it-or-hate-it reputation is strapping in for not one but two hefty conferences. They've circled November 19 and December 1, 2026, on...

Continue Reading
Chicken Production Rises Amid Meat Market Shifts

Updated Category News Views 41

Protein Markets Scramble: Chicken Production Climbs Here’s a tasty tidbit that might just have investors reeling: the USDA says chicken production will be cruising on the up, whereas beef is taking a bit of a backseat. Yep, the big birds are flying higher, and the cows, well, they're just mooing a little softer. And what's that mean for big players like Tyson...

Continue Reading
Caregiving's Financial Impact on Women: Insights from Cinergy

Updated Category News Views 96

Women Caregivers Face Financial Crossroads When it comes down to it, caregiving is one heck of a responsibility, particularly for women. It's about the sacrifices they make, not just in time but in financial security, too. Step away from a job to care for someone, and it's a dicey game you're playing with future income. The Cost of Generosity: Financial Impacts Cindy...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 242

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Lennar Faces Legal Heat Over Alleged Misleading Statements

Updated Category News Views 78

Rumbling Legal Drama with Lennar Corporation Every trader knows the uneasy feeling when a stock you're eyeing takes a surprising nosedive on some legal muck coming out of the woodwork. Well, it's Lennar Corporation's turn in the spotlight for all the wrong reasons. They're getting slapped with a class action lawsuit by investors claiming the company pulled a fast one...

Continue Reading
SahajMobile's $25M Boost: Impact on Bangladesh Market

Updated Category News Views 98

Untapped Digital Frontier in Bangladesh There's an undeniable buzz around SahajMobile's recent $25 million credit facility, and it's one worth dissecting. This shot of capital, lined up with ALMA as part of SahajMobile’s Series A gamble, is setting the stage for a real shuffle in Bangladesh's digital landscape. Plugging into a Market Gap Ever since it hit the ground...

Continue Reading
Panasonic Showcases Rugged Tech at NATO Edge 26

Updated Category News Views 41

Panasonic Heads to Turkey with Tactical Tech Panasonic's got its sights set on proving a point at NATO Edge 26, busting out its TOUGHBOOK line and showing just how these rugged laptops aren't just tough, but also strategically essential. From November 17th through 19th, down in Turkey, these devices are taking the spotlight as they embrace the operational challenges of...

Continue Reading
Mars Moves on Cash Tender Offers for Seniors' Notes

Updated Category News Views 104

A Strategic Financial Maneuver or a Casual Gambit? Okay, what’s Mars up to now, you ask? Here we go with this. The behemoth behind some of your favorite snacks and pet indulgences is making waves—not with candy, but with cash. Mars, Incorporated is rolling out tender offers to buy back a substantial chunk of its Senior Notes for $2 billion in cold, hard cash. When a...

Continue Reading

Top 5 Most Recently Viewed Articles

Jefferies Reports Optimism for Vertiv's Future Growth Potential

Updated Category News Views 95

Jefferies Boosts Vertiv Holdings Co. Stock Outlook Recently, Vertiv Holdings Co. (NYSE: VRT), known for its vital role in digital infrastructure and continuity solutions, captured attention with its promising assessment by Jefferies, a prominent financial firm. Jefferies has initiated coverage on Vertiv with a favorable Buy rating, establishing an ambitious price target...

Continue Reading
BioAdaptives: A New Era Ahead Post-Reverse Stock Split

Updated Category News Views 212

Transforming BioAdaptives for a Brighter Future In a recent update, BioAdaptives, Inc. has provided shareholders with insights regarding a key decision that impacts its future direction. After experiencing significant growth in the number of its outstanding shares without corresponding revenue growth, management recognizes the urgent need for a strategic pivot. The...

Continue Reading
Explore Spacious Model Homes at The Timbers for Active Adults

Updated Category News Views 49

Introducing The Timbers at Everlands Lennar, a prominent name in homebuilding, is excited to announce the grand opening of new model homes at The Timbers at Everlands, an innovative community tailored for active adults. These stunning homes offer three distinct styles as well as numerous amenities that cater to comfort and lively living. A Vibrant Community for Active...

Continue Reading
Emerging Innovations in the Tire Technologies Market

Updated Category News Views 410

The Evolution of Tire Technologies in a New Era As electric vehicles (EVs) transform the world of transportation, the tire sector is witnessing a crucial revolution. Gone are the days when tires were merely black rubber circles; today, they are integral to vehicle performance, providing not just grip but also intelligence. With innovations in tire design and technology,...

Continue Reading
Streamlined Emergency Cash Options: Wizzay's New Features

Updated Category News Views 209

Introducing Wizzay's 1-Hour Payday Loans In today's fast-paced world, unexpected expenses can arise at any moment. Wizzay has rolled out a groundbreaking solution for those looking for quick access to funds: 1-hour payday loans that don't involve hard credit checks. This new program is tailored for individuals who require immediate financial assistance, with many...

Continue Reading